Form 8-K

8-K — Insight Molecular Diagnostics Inc.

Accession: 0001493152-26-043560

Filed: 2026-09-21

Period: 2026-09-15

CIK: 0001642380

SIC: 2835 (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES)

Item: Entry into a Material Definitive Agreement

Item: Financial Statements and Exhibits

Documents

8-K — form8-k.htm (Primary)

EX-2.1 (ex2-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: form8-k.htm · Sequence: 1

false

0001642380

2026-09-15

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

FORM

8-K

Current

Report

Pursuant

to Section 13 or 15(d) of the

Securities

Exchange Act of 1934

Date

of Report (Date of earliest event reported): September 15, 2026

Insight

Molecular Diagnostics Inc.

(Exact

name of Registrant as specified in its charter)

California

1-37648

27-1041563

(State

or other jurisdiction

of incorporation)

(Commission

File No.)

(IRS

Employer

Identification No.)

International Plaza Dr., Suite 510

Nashville,

Tennessee 37217

(Address

of principal executive offices) (Zip code)

(615)

255-8880

Registrant’s

telephone number, including area code

Check

the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under

any of the following provisions:

☐

Written

communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting

material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement

communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement

communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities

Registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common

stock, no par value

IMDX

The

Nasdaq Stock Market LLC

Indicate

by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405

of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging

growth company ☐

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying

with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item

1.01 Entry into a Material Definitive Agreement.

previously reported, Insight Molecular Diagnostics Inc. (the “Company” or “iMDx”) entered into an Agreement

and Plan of Merger dated February 2, 2021, amended February 23, 2021, and amended and restated as of April 15, 2021 (as amended and restated,

the “Merger Agreement”), by and among the Company, CNI Monitor Sub, Inc., a Delaware corporation and wholly-owned subsidiary

of the Company (“Merger Sub”), Chronix, the stockholders party to the Merger Agreement (the “Stockholders”) and

the equity holder representative. Pursuant to the Merger Agreement, Merger Sub merged with and into Chronix, with Chronix surviving as

a wholly-owned subsidiary of the Company (the “Merger”). The Merger was completed on April 15, 2021. Pursuant to the Merger

Agreement, in addition to closing consideration, the Company agreed to pay Chronix’s equity holders (i) up to $14 million in any

combination of cash or common stock if certain milestones are achieved (the “Milestone Payments”), (ii) earnout consideration

during the five to ten-year earnout periods of up to 15% of net collections for sales of specified tests and products (the “15%

Royalty”), and (iii) up to 75% of net collections from the sale or license to a third party of Chronix’s patents for use

in transplantation medicine during a seven-year earnout period (the “Transplant Transfer Payout”).

previously reported, on February 8, 2023, the Company and equity holder representative entered into Amendment No. 1 to the Merger Agreement,

pursuant to which the parties agreed that (i) Chronix’s equity holders will be paid earnout consideration of 10% of net collections

(the “10% Royalty”) for sales of specified tests and products (including those that use Chronix’s patented technology

involving copy number instability to sensitively quantify the cell-free DNA from the primary solid tumor in a patient’s blood (“CNI

Monitor”)), until the expiration of intellectual property related to such tests and products, (ii) Chronix’s equity holders

will be paid 5% of the gross proceeds received from any sale of all or substantially all of the rights, titles, and interests in and

to Chronix’s patents for use in transplantation medicine to such third party, and (iii) the Milestone Payments, 15% Royalty and

Transplant Transfer Payout obligations were eliminated.

September 15, 2026, iMDx and equity holder representative entered into Amendment No. 2 to the Merger Agreement (“Amendment No.

2”), pursuant to which the parties agreed that (i) Chronix’s equity holders will be paid a 10% Royalty for sales of CNI Monitor,

until the earlier of (a) a sale of all or substantially all of the rights, titles, and interests in and to CNI Monitor to a third party

(a “CNI Monitor Sale”), and (b) expiration of intellectual property related to CNI Monitor, and (ii) upon a CNI Monitor Sale,

Chronix’s equity holders will be paid a final payment of 10% of the gross proceeds received from such CNI Monitor Sale (the “CNI

Monitor Sale Payment”). In effect, upon payment of the CNI Monitor Sale Payment in connection with a CNI Monitor Sale, the ongoing

10% Royalty with respect to CNI Monitor will terminate.

The

foregoing summary of Amendment No. 2 and the transactions contemplated by Amendment No. 2 does not purport to be complete and is qualified

in its entirety by reference to the full text of the Amendment No. 2, which is filed as Exhibit 2.1 hereto and is incorporated herein

by reference.

Item

9.01 Financial Statements and Exhibits.

(d)

Exhibits

Exhibit

Number

Description

2.1

Amendment No. 2 to Amended and Restated Agreement and Plan of Merger dated September 15, 2026, by and between Insight Molecular Diagnostics Inc. and David MacKenzie, solely in his capacity as Equityholder Representative

104

Cover

Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant

to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by

the undersigned hereunto duly authorized.

INSIGHT

MOLECULAR DIAGNOSTICS INC.

Date:

September 21, 2026

By:

/s/

Peter Hong

Name:

Peter

Hong

Title:

Vice

President, General Counsel

EX-2.1

Filename: ex2-1.htm · Sequence: 2

Exhibit

2.1

AMENDMENT

NO. 2 TO AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER

This

AMENDMENT NO. 2 TO AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER, dated as of September 15, 2026 (this “Amendment No. 2”),

is entered into by and between Insight Molecular Diagnostics Inc. (formerly known as Oncocyte Corporation), a California corporation

(“Parent”), and David MacKenzie, solely in his capacity as the equityholder representative (the “Equityholder

Representative”) under the Merger Agreement (as defined below). Initially capitalized terms used in this Amendment No. 2 and

not otherwise defined will have the meanings set forth in the Merger Agreement.

RECITALS

WHEREAS,

Parent, CNI Monitor Sub, Inc., a Delaware corporation and wholly-owned subsidiary of Parent, Chronix

Biomedical, Inc., a Delaware corporation (“Chronix”), certain stockholders of Chronix and the Equityholder Representative

entered into an Agreement and Plan of Merger, dated as of February 2, 2021, as amended as of February 23, 2021, as amended and restated

as of April 15, 2021 and as amended as of February 8, 2023 (the “Merger Agreement”);

WHEREAS,

pursuant to Section 11.10 of the Merger Agreement, after the Effective Time, the Merger Agreement

may be amended, modified or supplemented by an agreement in writing signed by Parent and the Equityholder Representative; and

WHEREAS,

Parent and Equityholder Representative have agreed to amend, modify and supplement the Merger Agreement,

including without limitation with respect to the Earnout Consideration and other Additional Payments set forth in Section 2.12

thereof and on Schedule 2.12 attached thereto.

NOW

THEREFORE, in consideration of the premises set forth above, the mutual promises and covenants set forth herein and other for good

and valuable consideration receipt of which is acknowledged, the Parties hereby agree as follows:

1. Amendment

to the Merger Agreement

1.1 Section

2.12(a) of the Merger Agreement is hereby deleted entirely and replaced with the following:

“Subject

to offset for (a) the Equityholders’ indemnification obligations as set forth in Article IX (including in any Notice of

Claim timely given) and/or (b) payment of Restructured Liabilities and Excess Liabilities in accordance with Article II, the Equityholders

shall be entitled to receive Additional Payments set forth on Schedule 2.12 attached hereto. Schedule 2.12 shall set forth

the terms and conditions pursuant to which Parent, the Surviving Corporation, and/or a Third Party acquiror of the CNI Monitor or the

Transplant IP, as applicable, will pay Earnout Consideration equal to ten percent (10%) of Net Collected Sales of CNI Monitor, Company

Pharma Tests, and Company Transplant IP. Notwithstanding anything in this Agreement to the Contrary, (i) if Parent or an Affiliate of

Parent consummates a Transplant IP Sale, then Parent, its Affiliate, or the Third Party that acquired such Company Transplant IP, shall

make an Earnout Consideration payment in cash equal to five percent (5%) of the Transplant IP Purchase Price, payable no later than two

(2) Business Days after payment of the Transplant IP Purchase Price (the “Transplant IP Sale Payment”), and (ii) if

Parent or an Affiliate of Parent consummates a CNI Monitor Sale, then Parent, its Affiliate, or the Third Party that acquired

the CNI Monitor, shall make an Earnout Consideration payment in cash equal to ten percent (10%) of the CNI Monitor Purchase Price, payable

no later than two (2) Business Days after payment of the CNI Monitor Purchase Price (the “CNI Monitor Sale Payment”).

The “Transplant IP Purchase Price” means the gross proceeds from a Transplant IP Sale, specifically including any

subsequent payments to be paid after the closing of such Transplant IP Sale (e.g. contingent payments, earnouts, etc.). The “CNI

Monitor Purchase Price” means the gross proceeds from a CNI Monitor Sale, specifically including any subsequent payments to

be paid after the closing of such CNI Monitor Sale (e.g. contingent payments, earnouts, etc.). Notwithstanding anything else in this

Agreement to the contrary, (A) upon the payment to the Equityholders in accordance with this Section 2.12(a), Schedule 2.12

and Section 2.13 of the CNI Monitor Sale Payment that is due and payable after the closing of the CNI Monitor Sale, neither Parent

nor any of its Affiliates shall have any further obligations, nor shall any Equityholder have any further rights or entitlements, in

each case, under this Agreement with respect to any Earnout Consideration or any Additional Payment arising out of or related to a CNI

Monitor Sale or any future sales of CNI Monitor (including any Net Collected Sales of CNI Monitor), and all such rights and obligations

shall be permanently and irrevocably terminated and extinguished without the necessity of any additional action on the part of any Person;

(B) in no event shall the foregoing clause (A) affect any rights or obligations of Parent, its Affiliates or any Equityholder with respect

to any Earnout Consideration or any Additional Payments that may become due and payable under this Agreement with respect to the Company

Pharma Tests or the Company Transplant IP; and (C) for purposes of the Additional Payments set forth in this Section 2.12(a) and

Schedule 2.12 attached hereto, any such Additional Payments that become due and payable to an Equityholder shall be payable solely

in cash.

-1-

The

obligation to pay ten percent (10%) of Net Collected Sales of Company Transplant IP shall be assumed by the Third Party acquiror in the

Transplant IP Sale, provided that Equityholder Representative shall be an express third-party beneficiary of the agreement(s) governing

the Transplant IP Sale.

The

obligation to pay ten percent (10%) of Net Collected Sales of Company Pharma Tests shall be assumed by the Third Party acquiror in the

Company Pharma Test Sale, provided that Equityholder Representative shall be an express third-party beneficiary of the agreement(s) governing

the Company Pharma Test Sale. “Company Pharma Test Sale” means the sale by Parent and/or any Affiliate of Parent of

all or substantially all of the rights, titles, and interests in and to the Company Pharma Tests, in one or a series of transactions.

For

the avoidance of doubt, in no event shall the obligation to pay ten percent (10%) of Net Collected Sales of CNI Monitor be assumed by

the Third Party acquiror in a CNI Monitor Sale.

2. Amendment

to Schedule 2.12 to the Merger Agreement

Schedule

2.12 to the Merger Agreement is hereby deleted entirely and replaced with Schedule 2.12 attached hereto.

3. No

Other Change

Except

as contemplated by this Amendment No. 2, the Parties hereby acknowledge and agree that the other terms and provisions of the Merger Agreement

shall not be affected and shall continue in full force and effect.

4. Counterparts,

Signatures

This

Amendment No. 2 may be executed in any number of counterparts, each such counterpart being deemed to be an original instrument, and all

such counterparts shall together constitute the same agreement. This Amendment No. 2 may be executed and delivered by facsimile transmission

or by e-mail delivery of a “pdf” format data file, and in the event this Amendment No. 2 is so executed and delivered, such

signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the

same force and effect as if such facsimile or “pdf” signature page were an original thereof.

[Signature

Page Follows.]

-2-

WITNESS WHEREOF, Parent and the Equityholder Representative have caused this Amendment No. 2 to be signed by their respective officers

or representatives thereunto duly authorized as of the date first written above.

Parent:

INSIGHT

MOLECULAR DIAGNOSTICS INC.

By:

/s/

Josh Riggs

Name:

Josh

Riggs

Title:

Chief

Executive Officer

Equityholder

Representative:

/s/

David MacKenzie

David

MacKenzie

[Signature Page to Amendment No.2 to Amended and Restated

Merger Agreement]

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.3

Cover

Sep. 15, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Sep. 15, 2026

Entity File Number

1-37648

Entity Registrant Name

Insight

Molecular Diagnostics Inc.

Entity Central Index Key

0001642380

Entity Tax Identification Number

27-1041563

Entity Incorporation, State or Country Code

Entity Address, Address Line One

International Plaza Dr.

Entity Address, Address Line Two

Suite 510

Entity Address, City or Town

Nashville

Entity Address, State or Province

Entity Address, Postal Zip Code

37217

City Area Code

(615)

Local Phone Number

255-8880

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common

stock, no par value

Trading Symbol

IMDX

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration